Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus
about
Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE)Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.Management of cardiovascular complications in systemic lupus erythematosus.Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study.Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease.Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.Endothelial dysfunction in chronic inflammatory diseasesThe interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammationAutologous stem cell transplantation in autoimmune and rheumatic diseases: from the molecular background to clinical applications.Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.Sucrose non-fermenting AMPK related kinase/Pentraxin 3 and DNA damage axis: a gateway to cardiovascular disease in systemic lupus erythematosus among Egyptian patients.Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.Cardiovascular disease complications in systemic lupus erythematosus.Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus.Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1β Pathway in Systemic Lupus Erythematosus.Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus.Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.
P2860
Q30973856-9F287756-E69E-4DE5-99D4-A36E3C3AD18AQ33387473-78BDAE5D-88E0-45F2-B1EC-0C311FAE8E86Q33730536-E83F18C9-6349-43EA-86DF-EAF924889234Q33766242-C16A66C0-5783-497F-A517-7498DE405F23Q34027430-70D1D6D5-54FA-4B9C-91F7-510855B0CD00Q34027495-822BACE4-CE77-4591-A5C2-453112BA08B9Q34072179-CAC7DF80-477A-43A7-B7C7-04D6665AC09DQ35169351-16B39144-4C9D-4D71-82F6-DD10C4722954Q35557372-46A5D089-116A-43DF-A573-9B902E978A78Q37687432-71DF4DCD-71F0-4182-9F1A-85CAF30837E0Q38162490-4FD03F4C-6903-4742-BD0A-4E5F9982F6DEQ39632598-9F8DA19B-FDD0-4D8E-ABF4-23BC8E2F82B0Q41260389-D1CFDB8F-628B-459A-87F1-14692733656DQ43061600-B62B649C-999A-47C4-A83F-D8BADD7171DFQ43173649-F34DD66C-4BA0-473E-ACFD-1592DCE7E284Q47871866-5D22F84F-400C-4EEF-AFC8-D6A6C1431D96Q48858141-6808FE90-CE9B-4985-8CBD-E8D1D2D6351AQ50985903-086A32F8-0279-403E-81F7-E6DDAA2A84B0Q52316454-FC90F91E-176A-4941-B599-D41274B51E2C
P2860
Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2008
@uk
name
Endothelial function and marke ...... n systemic lupus erythematosus
@en
Endothelial function and marke ...... n systemic lupus erythematosus
@nl
type
label
Endothelial function and marke ...... n systemic lupus erythematosus
@en
Endothelial function and marke ...... n systemic lupus erythematosus
@nl
prefLabel
Endothelial function and marke ...... n systemic lupus erythematosus
@en
Endothelial function and marke ...... n systemic lupus erythematosus
@nl
P2093
P2860
P1476
Endothelial function and marke ...... n systemic lupus erythematosus
@en
P2093
A. Cederholm
J. Frostegård
K. Jensen‐Urstad
P2860
P304
P356
10.1080/03009740802007514
P577
2008-01-01T00:00:00Z